MX2022001450A - Metodo de tratamiento del cancer. - Google Patents
Metodo de tratamiento del cancer.Info
- Publication number
- MX2022001450A MX2022001450A MX2022001450A MX2022001450A MX2022001450A MX 2022001450 A MX2022001450 A MX 2022001450A MX 2022001450 A MX2022001450 A MX 2022001450A MX 2022001450 A MX2022001450 A MX 2022001450A MX 2022001450 A MX2022001450 A MX 2022001450A
- Authority
- MX
- Mexico
- Prior art keywords
- treatment method
- cancer treatment
- patient
- prostate cancer
- resistant
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 2
- 238000011282 treatment Methods 0.000 title abstract 2
- 206010028980 Neoplasm Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 206010060862 Prostate cancer Diseases 0.000 abstract 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 abstract 2
- ZVIFCOOHWGNPHJ-UHFFFAOYSA-N 1-(2-chloropyridin-4-yl)-3-(4-methylpyridin-3-yl)imidazolidin-2-one Chemical compound CC1=CC=NC=C1N1C(=O)N(C=2C=C(Cl)N=CC=2)CC1 ZVIFCOOHWGNPHJ-UHFFFAOYSA-N 0.000 abstract 1
- AFJRDFWMXUECEW-LBPRGKRZSA-N N-[(2S)-1-amino-3-(3-fluorophenyl)propan-2-yl]-5-chloro-4-(4-chloro-2-methyl-3-pyrazolyl)-2-thiophenecarboxamide Chemical compound CN1N=CC(Cl)=C1C1=C(Cl)SC(C(=O)N[C@H](CN)CC=2C=C(F)C=CC=2)=C1 AFJRDFWMXUECEW-LBPRGKRZSA-N 0.000 abstract 1
- 229950000079 afuresertib Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Steroid Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
La presente solicitud proporciona un método para tratar el cáncer de próstata resistente a la castración en un paciente, que comprende administrar al paciente una combinación de afuresertib y CFG920, en donde el cáncer de próstata resistente a la castración también es resistente a uno o más estándares de los tratamientos para el cuidado.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2019099754 | 2019-08-08 | ||
| PCT/US2020/045410 WO2021026454A1 (en) | 2019-08-08 | 2020-08-07 | Method of treating cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022001450A true MX2022001450A (es) | 2022-04-20 |
Family
ID=72234946
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022001450A MX2022001450A (es) | 2019-08-08 | 2020-08-07 | Metodo de tratamiento del cancer. |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US20210038578A1 (es) |
| EP (1) | EP4009969A1 (es) |
| JP (1) | JP7526783B2 (es) |
| KR (1) | KR20220047589A (es) |
| CN (1) | CN114080225A (es) |
| AU (1) | AU2020327022A1 (es) |
| BR (1) | BR112022001508A2 (es) |
| CA (1) | CA3148115A1 (es) |
| IL (1) | IL289811A (es) |
| MX (1) | MX2022001450A (es) |
| TW (1) | TWI857119B (es) |
| WO (1) | WO2021026454A1 (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7010330B1 (en) | 2003-03-01 | 2006-03-07 | Theta Microelectronics, Inc. | Power dissipation reduction in wireless transceivers |
| CN119013022A (zh) | 2022-03-14 | 2024-11-22 | 来凯有限公司 | 癌症的组合治疗 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2601675B1 (fr) | 1986-07-17 | 1988-09-23 | Rhone Poulenc Sante | Derives du taxol, leur preparation et les compositions pharmaceutiques qui les contiennent |
| AU668144B2 (en) | 1992-03-31 | 1996-04-26 | Btg International Limited | 17-substituted steroids useful in cancer treatment |
| MA23823A1 (fr) | 1995-03-27 | 1996-10-01 | Aventis Pharma Sa | Nouveaux taxoides, leur preparation et les compositions qui les contiennent |
| KR100786927B1 (ko) | 2000-06-28 | 2007-12-17 | 스미스클라인비이참피이엘시이 | 습식 분쇄방법 |
| US7709517B2 (en) | 2005-05-13 | 2010-05-04 | The Regents Of The University Of California | Diarylhydantoin compounds |
| LT3412290T (lt) | 2006-03-27 | 2021-04-26 | The Regents Of The University Of California | Androgeno receptorių moduliatorius, skirtas prostatos vėžio bei su androgeno receptoriais susijusių ligų gydymui |
| UY30892A1 (es) | 2007-02-07 | 2008-09-02 | Smithkline Beckman Corp | Inhibidores de la actividad akt |
| US8609711B2 (en) * | 2009-01-30 | 2013-12-17 | Glaxosmithkline Llc | Crystalline N-{(1S)-2-amino-1-[(3-fluorophenyl)methyl]ethyl}-5-chloro-4-(4-chloro-1-methyl-1H-pyrazol-5-yl)-2-thiophenecarboxamic hydrochloride |
| JP5456891B2 (ja) * | 2009-06-26 | 2014-04-02 | ノバルティス アーゲー | Ｃｙｐ１７阻害剤としての１，３−二置換イミダゾリジン−２−オン誘導体 |
| AR078793A1 (es) | 2009-10-27 | 2011-12-07 | Orion Corp | Derivados de carboxamidas no esteroidales y acil hidrazona moduladores de receptores androgenicos de tejido selectivo (sarm), composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento del cancer de prostata entre otros |
| EP2858631A1 (en) * | 2012-06-06 | 2015-04-15 | Novartis AG | Combination of a 17 -alpha -hydroxylase (c17, 20 - lyase) inhibitor and a specific pi-3k inhibitor for treating a tumor disease |
| US20160228456A1 (en) | 2013-10-01 | 2016-08-11 | Novartis Ag | Combination |
| CN108112235A (zh) * | 2015-03-06 | 2018-06-01 | 克利夫兰临床基金会 | 改变类固醇代谢以用于治疗类固醇依赖性疾病 |
-
2020
- 2020-08-07 WO PCT/US2020/045410 patent/WO2021026454A1/en active IP Right Grant
- 2020-08-07 BR BR112022001508A patent/BR112022001508A2/pt unknown
- 2020-08-07 AU AU2020327022A patent/AU2020327022A1/en active Pending
- 2020-08-07 US US16/987,924 patent/US20210038578A1/en not_active Abandoned
- 2020-08-07 EP EP20761400.9A patent/EP4009969A1/en active Pending
- 2020-08-07 MX MX2022001450A patent/MX2022001450A/es unknown
- 2020-08-07 KR KR1020227007678A patent/KR20220047589A/ko active Pending
- 2020-08-07 TW TW109126973A patent/TWI857119B/zh active
- 2020-08-07 JP JP2022507799A patent/JP7526783B2/ja active Active
- 2020-08-07 CA CA3148115A patent/CA3148115A1/en active Pending
- 2020-08-07 CN CN202080048545.3A patent/CN114080225A/zh active Pending
-
2022
- 2022-01-12 IL IL289811A patent/IL289811A/en unknown
-
2024
- 2024-12-04 US US18/968,073 patent/US20250090514A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2022543679A (ja) | 2022-10-13 |
| US20210038578A1 (en) | 2021-02-11 |
| IL289811A (en) | 2022-03-01 |
| CN114080225A (zh) | 2022-02-22 |
| CA3148115A1 (en) | 2021-02-11 |
| AU2020327022A1 (en) | 2022-02-10 |
| JP7526783B2 (ja) | 2024-08-01 |
| US20250090514A1 (en) | 2025-03-20 |
| AU2020327022A8 (en) | 2022-06-30 |
| BR112022001508A2 (pt) | 2022-07-12 |
| TW202120086A (zh) | 2021-06-01 |
| KR20220047589A (ko) | 2022-04-18 |
| WO2021026454A1 (en) | 2021-02-11 |
| EP4009969A1 (en) | 2022-06-15 |
| TWI857119B (zh) | 2024-10-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2023000735A (es) | Metodos y combinaciones de inhibidor de kat6 para el tratamiento del cancer. | |
| MX2023001527A (es) | Compuestos con actividad inductora de ferroptosis y metodos de uso de estos. | |
| DOP2012000155A (es) | Terapia combinada para el tratamiento del cancer y ensayos de diagnostico relacionados | |
| MX2020009773A (es) | Terapia de combinacion. | |
| PH12020551427A1 (en) | Epinephrine spray formulations | |
| MX387283B (es) | Tratamiento del cancer con tg02. | |
| MX2017000628A (es) | Metodos para tratar pacientes de alto riesgo cardiovascular con hipercolesterolemia. | |
| MX2021010173A (es) | Compuestos con actividad inductora de ferroptosis y métodos de uso. | |
| MX2023012515A (es) | Tratamiento del cancer con un inhibidor de raf. | |
| MX2023004156A (es) | Terapia combinada para el tratamiento del cancer. | |
| MX2020001727A (es) | Terapia de combinacion. | |
| CR20210514A (es) | USO DE REBOXETINA PARA EL TRATAMIENTO DE NARCOLEPSIA (Divisional 2021-0183) | |
| CL2020001888A1 (es) | Terapia de combinación para tratar o prevenir el cáncer. | |
| MX2022001450A (es) | Metodo de tratamiento del cancer. | |
| CL2021001623A1 (es) | Terapia de combinación con un inhibidor de raf y un inhibidor de cdk4/6 para utilizar en el tratamiento del cáncer | |
| CL2021001976A1 (es) | Tratamiento de lesiones cutáneas y prurito en pacientes con prurigo nodular | |
| DOP2023000155A (es) | Tratamiento y terapia de mantenimiento para el cáncer de vejiga con gemcitabina | |
| MX2021005876A (es) | Elacestrant en combinacion con abemaciclib en mujeres con cancer de mama. | |
| MX2018012392A (es) | Terapias de combinacion para el tratamiento de cancer que comprenden un derivado de bacterioclorofila. | |
| MX2020008881A (es) | Métodos de tratamiento contra el cáncer que comprenden inhibidores de chk1. | |
| UY39203A (es) | Tratamientos del cáncer de próstata con combinaciones de acetato de abiraterona y niraparib | |
| CL2023003090A1 (es) | Combinaciones de composiciones terapéuticas y usos para tratar cánceres | |
| MX2019014934A (es) | Combinación de vorasidenib con radiación y/o agentes adicionales para tratar gliomas. | |
| MX2018003308A (es) | Suministro localizado de agente anti-fuctactico para tratamiento del cancer. | |
| MX393475B (es) | Uso de una combinación de ivosidenib y radiación para tratar gliomas. |